title: Rivastigmine: a review.
abstract: The acetylcholinesterase inhibitors are the first useful and useable drugs for palliative treatment of dementia of the Alzheimer type. This article reviews the second-generation carbamate cholinesterase inhibitor, rivastigmine (EXELON, Novartis, Basel) whose distinctive pharmacology is not only of immediate clinical relevance but also the key to some tantalizing therapeutic possibilities.
authors.affiliation: Udston Hospital, Hamilton, Lanarkshire.
authors.forename: A
authors.initials: A
authors.lastname: Sim
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism; D002219:Carbamates / Q000378:metabolism / Q000627:therapeutic use*; D002800:Cholinesterase Inhibitors / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D048448:Phenylcarbamates; D000068836:Rivastigmine; D016896:Treatment Outcome
chemical_list: D002219:Carbamates; D002800:Cholinesterase Inhibitors; D048448:Phenylcarbamates; D000068836:Rivastigmine